Medios AG Achieves Record Third Quarter in 2024

In the third quarter of 2024, Medios AG reported a record EBITDA pre1 of €24.6 million, marking a 42.9% increase from the previous year. This resulted in an EBITDA pre1 margin of 5.0%, the highest in the company's history. Revenue for the same period increased by 0.7% to €493.2 million. The Patient-Specific Therapies segment showed a more than 10% rise in EBITDA pre1, contributing positively despite a 3.5% drop in revenue.

The nine-month revenue for 2024 rose by 4.2% to €1,400.5 million, with EBITDA pre1 up by 20.6%. Operating cash flow improved significantly to €27.6 million. The integration of Ceban Pharmaceuticals boosted the International Business segment, contributing €9.8 million to the group’s earnings.

Looking ahead, Medios expects 2024 revenue between €1.9 billion and €2.1 billion, with EBITDA pre1 forecasted at €82 million to €91 million. Growth will be driven by continued expansion and strategic initiatives, including Advanced Therapies.